Bariatric endoscopy: State-of-the-art

Vivek Kumbhari, Christine Hill, Shelby Sullivan

Research output: Contribution to journalReview article

Abstract

Purpose of review: This review aims to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoscopic bariatric and metabolic procedures. Recent findings: There are an increasing number of devices and techniques that are available for the endoluminal treatment of obesity. It is now possible to offer FDA approved endoscopic therapies for patients with BMI as high as 55 kg/m2. Although tremendous advances have been made, there is room for additional emphasis with regards to the metabolic improvements seen with these therapies, in addition to highlighting weight loss outcomes. Furthermore, for optimal outcomes, it is imperative that all endoluminal techniques are combined with at least a moderate intensity diet and lifestyle intervention for a minimum of 12 months. Summary: This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Owing to its minimally invasive nature, endoscopic metabolic and bariatric therapy has the potential to appeal patients who either do not qualify or do not want bariatric surgery and have not been adequately treated with medical therapy. In addition, these therapies may be beneficial early on in the onset of obesity.

Original languageEnglish (US)
Pages (from-to)358-365
Number of pages8
JournalCurrent Opinion in Gastroenterology
Volume33
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Bariatrics
Endoscopy
Bariatric Surgery
Obesity
Therapeutics
Life Style
Counseling
Weight Loss
Diet
Equipment and Supplies

Keywords

  • aspiration therapy
  • endoscopic sleeve gastroplasty
  • gastrointestinal bypass sleeve
  • intragastric balloon
  • transoral gastroplasty

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bariatric endoscopy : State-of-the-art. / Kumbhari, Vivek; Hill, Christine; Sullivan, Shelby.

In: Current Opinion in Gastroenterology, Vol. 33, No. 5, 01.09.2017, p. 358-365.

Research output: Contribution to journalReview article

Kumbhari, Vivek ; Hill, Christine ; Sullivan, Shelby. / Bariatric endoscopy : State-of-the-art. In: Current Opinion in Gastroenterology. 2017 ; Vol. 33, No. 5. pp. 358-365.
@article{ce080ed2de344ae9a7f2dfd707149f28,
title = "Bariatric endoscopy: State-of-the-art",
abstract = "Purpose of review: This review aims to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoscopic bariatric and metabolic procedures. Recent findings: There are an increasing number of devices and techniques that are available for the endoluminal treatment of obesity. It is now possible to offer FDA approved endoscopic therapies for patients with BMI as high as 55 kg/m2. Although tremendous advances have been made, there is room for additional emphasis with regards to the metabolic improvements seen with these therapies, in addition to highlighting weight loss outcomes. Furthermore, for optimal outcomes, it is imperative that all endoluminal techniques are combined with at least a moderate intensity diet and lifestyle intervention for a minimum of 12 months. Summary: This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Owing to its minimally invasive nature, endoscopic metabolic and bariatric therapy has the potential to appeal patients who either do not qualify or do not want bariatric surgery and have not been adequately treated with medical therapy. In addition, these therapies may be beneficial early on in the onset of obesity.",
keywords = "aspiration therapy, endoscopic sleeve gastroplasty, gastrointestinal bypass sleeve, intragastric balloon, transoral gastroplasty",
author = "Vivek Kumbhari and Christine Hill and Shelby Sullivan",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/MOG.0000000000000383",
language = "English (US)",
volume = "33",
pages = "358--365",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Bariatric endoscopy

T2 - State-of-the-art

AU - Kumbhari, Vivek

AU - Hill, Christine

AU - Sullivan, Shelby

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of review: This review aims to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoscopic bariatric and metabolic procedures. Recent findings: There are an increasing number of devices and techniques that are available for the endoluminal treatment of obesity. It is now possible to offer FDA approved endoscopic therapies for patients with BMI as high as 55 kg/m2. Although tremendous advances have been made, there is room for additional emphasis with regards to the metabolic improvements seen with these therapies, in addition to highlighting weight loss outcomes. Furthermore, for optimal outcomes, it is imperative that all endoluminal techniques are combined with at least a moderate intensity diet and lifestyle intervention for a minimum of 12 months. Summary: This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Owing to its minimally invasive nature, endoscopic metabolic and bariatric therapy has the potential to appeal patients who either do not qualify or do not want bariatric surgery and have not been adequately treated with medical therapy. In addition, these therapies may be beneficial early on in the onset of obesity.

AB - Purpose of review: This review aims to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoscopic bariatric and metabolic procedures. Recent findings: There are an increasing number of devices and techniques that are available for the endoluminal treatment of obesity. It is now possible to offer FDA approved endoscopic therapies for patients with BMI as high as 55 kg/m2. Although tremendous advances have been made, there is room for additional emphasis with regards to the metabolic improvements seen with these therapies, in addition to highlighting weight loss outcomes. Furthermore, for optimal outcomes, it is imperative that all endoluminal techniques are combined with at least a moderate intensity diet and lifestyle intervention for a minimum of 12 months. Summary: This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Owing to its minimally invasive nature, endoscopic metabolic and bariatric therapy has the potential to appeal patients who either do not qualify or do not want bariatric surgery and have not been adequately treated with medical therapy. In addition, these therapies may be beneficial early on in the onset of obesity.

KW - aspiration therapy

KW - endoscopic sleeve gastroplasty

KW - gastrointestinal bypass sleeve

KW - intragastric balloon

KW - transoral gastroplasty

UR - http://www.scopus.com/inward/record.url?scp=85022003412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022003412&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000383

DO - 10.1097/MOG.0000000000000383

M3 - Review article

C2 - 28682794

AN - SCOPUS:85022003412

VL - 33

SP - 358

EP - 365

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 5

ER -